NightWare Launches Campaign to Disrupt Nightmares
FDA-Cleared Digital Therapeutic Treats PTSD Nightmares
Minneapolis, MN (December 4, 2024) – NightWare, the manufacturer of the FDA-cleared digital therapeutic device that treats PTSD-related nightmares, announced today that is has launched an equity crowdfunding campaign on StartEngine.
The NightWare device is a dedicated non-invasive medical device using an AI algorithm that identifies when a nightmare is occurring and nudges the user out of the nightmare without waking them.
“We are very excited about this campaign,” says NightWare CEO Matthew Tucker. “The raise supports our mission to improve sleep health for PTSD sufferers.”
The NightWare device is an FDA Breakthrough Device and was cleared in 2020 by the FDA to treat Nightmare Disorder, a condition related to PTSD that is formally recognized in the DSM 5. The non-invasive, non-pharmaceutical NightWare device has helped over 1,500 sufferers to-date.
“While we are gratified that we have been able to help so many patients, we know that 80% of PTSD patients experience disturbing nightmares and that Nightmare Disorder is related to an increased risk of suicide,” explains Tucker. “This capital raise will help us expand access and provide relief to these sufferers with a wearable, non-invasive
therapeutic that can produce results within a matter of days, compared to weeks or months with conventional therapies.”
For more information on the campaign page.